Navigation Links
Shortage of funds for providing AIDS drug in Africa and India

The number of people on antiretroviral therapy has doubled to 1 million worldwide and tripled in Africa and Asia. Asia and Africa are two regions which are hit greatly by AIDS. Though, there is a immense increase in antiretroviral // treatment, it is still far less than the requirement, and the WHO goal to treat 3 million people by 2005, will never happen world wide critics say.

Reports, say that only 11% of those in Africa and 14% of those in Asia have access to AIDS drugs. In India, which has more than 5 million cases of HIV/AIDS, the drugs are available to fewer than 10% of those who need it. The WHO says a shortage of trained health workers, insufficient technical support and lack of reliable funds from donor countries are making it difficult to meet the ‘3 by 5’ goal set in 2003.

Source: Nature Medicine.
'"/>




Page: 1

Related medicine news :

1. Shortage of MMR vaccine
2. Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid
3. Acute Shortage Of Neurosurgeons In India: One Surgeon For Every 1 Million!
4. Doctor Training Undermined In Britain Due To Shortage Of Cadavers
5. Shortage Of Funds In Primary Care Trust In UK
6. Acute Shortage Of Dentists in UK: Oral Care for Elders To Suffer A Setback
7. School Children Put To Risk Due To Shortage Of Nurses
8. UK Committee Warns on Food Shortages Due to Flu Epidemic
9. Zimbabwe Faces Shortage Of AIDS Drugs
10. UK Doctors Fear Shortages Could Hit Public Health Drive
11. Silent Shortage Of Psychiatrists growing in the U.S.
Post Your Comments:
(Date:8/29/2008)...swire/ -- The following is a,statement by Matthew ...s:, For the second time in a month, Philip Morris... promotion of a concert in a developing country,af...ing in cigarette,marketing that appeals to childre...en forced to withdraw from,an August 30 reunion co...
(Date:8/29/2008)... to Benefit Muscular Dystrophy Research , ...8 -- Students, faculty and staff from http://www....rsey, raised $11,000 for muscular dystrophy resear... from the event are in support of local non-profit...nteer event was attended by more than 100 walkers,...
(Date:8/29/2008)...irstCall/ -- Landauer, Inc. (NYSE:,LDR) announced ...ar,quarterly cash dividend of $0.50 per share for ...ll be paid on October 3, 2008, to shareholders of,...andauer is the leading provider of analytical serv...adiation exposure. For more than 50 years,the Com...
(Date:8/29/2008)...ed from $250 to $19 million, NATICK, Mass., Aug. ...poration (NYSE: BSX ) today announced that the U....ents of Medtronic, Inc. (NYSE: MDT ),unenforceabl...f the patents,before the United States Patent and ...at certain Boston Scientific balloon,catheters and...
Breaking Medicine News(10 mins):Health News:Philip Morris International Forced to Drop Another Concert Sponsorship; Philippines Health Department Applauded for Taking Action 2Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3
... dementia in the elderly with typical symptoms bei...ioral changes. An early study of the drug rolipram...g Alzheimer's disease in people, according to a ne... treatment of a mouse form of AD with rolipram imp...
...ic nerve damage are at increased risk for sleep di...l impairment. The participants had their sleep-wak...sults were compared with those of 12 young subject...ered those with optic nerve disease were 20-times ...
...ant women suffer from depression and up to 35 perc... Studies involving infants exposed to anti –depres...o most doctors believe these drugs can be safely p...es have only compared major outcomes, such as phys...
...cement therapy among breast cancer survivors has b...nacceptably high rate of recurring or new cancers.... because more women are surviving the disease and ... symptoms as other women. The study was expected t...
Other Medicine News:
(Date:8/26/2008)...sent data from landmark SYNTAX clinical trial, NA...ton Scientific,Corporation (NYSE: BSX ) today ann...and press announcements at the European Society of...30 to September 3 in Munich, Germany., The Compan...trial,which compares percutaneous coronary interv...
(Date:8/26/2008)... 26 /- Semafore Pharmaceuticals Inc.,...ss on Targeted Therapies,in Cancer in Washington, ...eted kinase inhibitors that demonstrate significan...novel and proprietary molecular scaffold has been ...r the design of pan-PI3 kinase inhibitors,as well ...
(Date:8/26/2008)... Aug. 26 /- Healthpoint today announc...ate the effectiveness of a,widely prescribed enzym...nd,resulting scars. The pilot study was prompted, ...nce of hypertrophic scars and beneficial healing,p...ntment.(1,2), "Given the findings from the peer-r...
(Date:8/26/2008)..., Aug. 26 /- XTENT, Inc.,(N...ne-year follow-up data,from the CUSTOM II trial wa...eviewed journal, EuroIntervention. The lead author... University Medical Center Utrecht, Utrecht,The N...s from 13 clinical,sites across Europe., The one-...
Breaking Medicine Technology:Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4WuXi PharmaTech 28NYSE 3A WX 29 Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia 1338 1WuXi PharmaTech 28NYSE 3A WX 29 Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia 1338 2Genta Announces Presentation of New Clinical and Preclinical Data on Genasense 28R 29 at AACR NCI EORTC Targets Conference 1336 1Genta Announces Presentation of New Clinical and Preclinical Data on Genasense 28R 29 at AACR NCI EORTC Targets Conference 1336 2Genta Announces Presentation of New Clinical and Preclinical Data on Genasense 28R 29 at AACR NCI EORTC Targets Conference 1336 3Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 1Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 9
...2007 - Pfizer said today that,results showing pote...anoma, thyroid, liver, non-small cell lung (NSCLC)...- a type of advanced kidney,cancer - will be prese... Oncology (ASCO) annual meeting in Chicago., "Each...ent, so,it,s critical that physicians have the fle...
...007 - Mitopharm Corporation,Inc. (Pink Sheets:MTP... Professor Dr. Robert Ko published the beneficial ...isandrin B - a novel,discovery by Dr. Ko - on Isch..."SCHISANDRIN B PROTECTS AGAINST,MYOCARDIAL ISCHEMI...THIONE ANTIOXIDANT STATUS"; Yim and Ko; Molecular ...
Other Medicine Technology:New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 2New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 3New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 4New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 5Investigation Findings, Corroborated by Empirical Evidence of the,Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine,for Hundreds of Years, Support the Use of Schisandrin B in the,Prevention and Treatment of IHD 2Investigation Findings, Corroborated by Empirical Evidence of the,Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine,for Hundreds of Years, Support the Use of Schisandrin B in the,Prevention and Treatment of IHD 3
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...
Medicine Products: